• A
  • A
  • A
日本語 Help
Science and technology information site for articles, patents, researchers information, etc.
Advanced
search
ALL

Synonyms(0)

Find out more technical terms

Thesaurus Map Clips

ー



Please login to MyJ-GLOBAL to use J- GLOBAL.
Please register to create your MyJ-GLOBAL account, if you do not have one.
What is MyJ-GLOBAL?
Login Register now
Number of clips is over the max size. (Max number of Clips: 600)
Close
Reset
Go to 「How to search」 page
Advanced search: Search from
　
　Select basic information for advanced search
Free word
～
Chemical structure search
How to Search
NEW R FG i
C N O S F Cl Br I P X
JSME Molecular Editor by Peter Ertl and Bruno Bienfait
drag out MOL or RXN file
Import

MOLfile format is only available (V3000 format is not available)

              
Details
Related links
Search

Co-authoring Researcher

Co-inventing Researcher

Researcher similar to the Researcher

Article similar to the Researcher

Patent similar to the Researcher

Research Project similar to the Researcher

Article(J-GLOBAL estimation)

Patent(J-GLOBAL estimation)

Rchr
J-GLOBAL ID：201601013751019694   Update date: Dec. 10, 2024

Ochi Toshiki

オチ トシキ | Ochi Toshiki
Clips
Affiliation and department：
Ehime University Graduate School of Medicine Department of Hematology, Clinical Immunology and Infectious Diseases

About Ehime University Graduate School of Medicine Department of Hematology, Clinical Immunology and Infectious Diseases


Other affiliations (1)：
  • Ehime University  Division of Immune Regulation, Proteo - Science Center 
Research field  (2)： Hematology and oncology ,  Immunology
Research theme for competitive and other funds  (24)：
  • 2024 - 2027 新たなT細胞活性化シグナルに基づく新規キメラ抗原受容体の開発研究
  • 2024 - 2025 新規抗体産生プラットフォームの樹立とその応用
  • 2022 - 2025 Development of multifunctional CAR-T cell therapy using novel manufacturing technology of scFv
  • 2023 - 2024 免疫療法の効果を高めるuniversal抗体の開発
  • 2023 - 2024 有効性と安全性を両立する新規キメラ抗原受容体遺伝子の開発とがん治療への応用
Show all
Papers (51)：
  • Toshiki Ochi, Tatsuya Konishi, Katsuto Takenaka. Bispecific antibodies for multiple myeloma: past, present and future. International journal of hematology. 2024
  • Tatsuya Konishi, Toshiki Ochi, Katsuto Takenaka. [Development of novel bispecific antibody therapy for multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2024. 65. 5. 428-438
  • Tatsuya Konishi, Toshiki Ochi, Masaki Maruta, Kazushi Tanimoto, Yukihiro Miyazaki, Chika Iwamoto, Takashi Saitou, Takeshi Imamura, Masaki Yasukawa, Katsuto Takenaka. Reinforced anti-myeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with Bridging-BiTE. Blood. 2023. 142. 21. 1789-1805
  • Yuichiro Nakaya, Akinori Higaki, Toshiki Ochi, Tomoaki Nishikawa, Tomoki Fujisawa, Shigehiro Miyazaki, Yusuke Akazawa, Toru Miyoshi, Hiroshi Kawakami, Fumiyasu Seike, et al. Rare Presentation of β-Thalassemia Intermedia With a Phenotype of Dilated Cardiomyopathy. CJC open. 2023. 5. 5. 392-395
  • 宮崎 幸大, 末盛 浩一郎, 桑原 希, 谷口 裕美, 村上 忍, 小西 達矢, 名部 彰悟, 丸田 雅樹, 越智 俊元, 谷本 一史, et al. COVID-19発症後に4ヵ月以上SARS-CoV-2の持続排出を認めた同種造血幹細胞移植患者. 日本造血・免疫細胞療法学会雑誌. 2023. 12. 2. 129-132
ｍore...
MISC (104)：
  • 小西 達矢, 越智 俊元, 竹中 克斗. Bridging-BiTEによる多発性骨髄腫の新たな治療開発. 血液内科. 2024. 89. 2. 203-210
  • 越智俊元, 越智俊元. Development of effective CAR-T cell therapy targeting various malignancies and their microenvironments. SGHがん研究報告. 2024. 34
  • 加藤潤一, 越智俊元, 末盛浩一郎, 乗松真大, 小西達矢, 名部彰悟, 丸田雅樹, 山之内純, 高田清式, 竹中克斗. ART導入後に化学療法を併用し寛解維持しているHIV関連リンパ増殖性疾患. 日本エイズ学会誌. 2023. 25. 4
  • 西村謙一, 小西達也, 越智俊元, 渡辺隆太, 野田輝乙, 福本哲也, 三浦徳宣, 宮内勇貴, 菊川忠彦, 雑賀隆史. イピリムマブ・ニボルマブ併用療法においてCD21loB細胞は免疫学的有害事象の予測因子になりうる. 泌尿器科分子・細胞研究会プログラム・抄録集. 2023. 32nd
  • 江原愛実, 丸田雅樹, 小西達矢, 名部彰悟, 宮崎幸大, 越智俊元, 谷本一史, 山之内純, 竹中克斗. ベネトクラクス・アザシチジン療法で治療を行った急性巨核芽球性白血病. 臨床血液. 2023. 64. 6
ｍore...
Patents (6)：
ｍore...
Books (4)：
  • 血液疾患最新の治療
    南江堂 2019 ISBN:9784524260713
  • がん免疫療法の個別化を支える新・腫瘍免疫学
    羊土社 2019 ISBN:9784758103817
  • 血液フロンティア
    医薬ジャーナル社 2018
  • 血液フロンティア
    医薬ジャーナル社 2016
Lectures and oral presentations  (46)：
  • Different functionality of CD19 CAR-T cells after stimulation with various amounts of tumor cells.
    (The 86th JSH Annual Meeting 2024)
  • T-Cell Redirection Therapy with Talented Antibodies for Hematological Malignancies.
    (The 83rd Annual Meeting of the Japanese Cancer Association 2024)
  • Fine-tuned scFvs and optimized CAR-T cells -From a translational technology to the CAR-T discovery-
    (2024)
  • Suboptimal characteristics of CD19 CAR-T cells stimulated with high amounts of tumors.
    (2024)
  • Conventional CD19 CAR-T cells stimulated with high amounts of tumors show suboptimal functionality.
    (The 28th Annual Meeting of Japanese Association of Cancer Immunotherapy 2024)
ｍore...
Professional career (1)：
  • 医学博士 (愛媛大学)
Work history (9)：
  • 2022/07 - 現在 Ehime University Graduate School of Medicine Department of Hematology, Clinical Immunology and Infectious Diseases
  • 2020/07 - 現在 Optieum Biotechnologies Inc.
  • 2018/04 - 現在 Proteo - Science Center, Ehime University Division of Immune Regulation
  • 2016/04 - 2022/12 Ehime University Graduate School of Medicine Department of Hematology, Clinical Immunology and Infectious Diseases
  • 2011/09 - 2016/03 Princess Margaret Cancer Centre, University Health Network Tumor Immunotherapy Program Postdoctoral Fellow
Show all
Committee career (3)：
  • 2021/11 - 現在 日本がん免疫学会 評議員
  • 2019/09 - 現在 日本血液学会 評議員
  • 2017/10 - 現在 日本血液疾患免疫療法学会 評議員
Awards (6)：
  • 2016/05 - 7th JSH international symposium Best Oral Presentation Award
  • 2014/05 - University Health Network ORT Conference Travel Award
  • 2013/10 - OCI/PM Guglietti Immune Therapy Fellowship Award
  • 2011/12 - Abstract Achievement Award, 53rd annual meeting of American Society of Hematology
  • 2010/03 - 愛媛大学大学院医学系研究科 研究奨励賞
Show all
Association Membership(s) (8)：
日本輸血・細胞治療学会 ,  日本造血・免疫細胞療法学会 ,  日本臨床分子医学会 ,  日本骨髄腫学会 ,  日本血液疾患免疫療法学会 ,  日本がん免疫学会 ,  日本血液学会 ,  日本内科学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM